This content is machine translated Diabetic nephropathy Dapagliflozin and pioglitazone are not inferior as lone fighters The treatment of diabetic nephropathy (DN) has made significant progress in the past. Nevertheless, the number of diabetic patients who ultimately develop end-stage renal disease remains high. A combination of…
View Post 3 min This content is machine translated T2D: Pioglitazone as an add-on to metformin and dapagliflozin Effective strategy for improving blood glucose control Type 2 diabetes (T2D) is a progressive disease characterized by a deterioration in the function of pancreatic β-cells and increased insulin resistance. Although there are many diabetes medications on the…
View Post 4 min This content is machine translated Heart failure: ESC guideline update 2023 Treatment of HFmrEF – what’s new? The European Society of Cardiology (ESC) recently updated its guidelines. Consequently, based on the EMPEROR-Preserved and DELIVER trials, the use of SGLT-2 inhibitors is now recommended for all stages of…
View Post 5 min This content is machine translated Heart failure in type 2 diabetes Success story of SGLT-2 inhibitors – impressive evidence base. The SGLT(“sodium glucose-linked transporter”)-2 inhibitors have demonstrated cardioprotective effects in addition to antidiabetic effects. The current evidence supports the benefit of several agents of SGLT-2-i in the treatment of heart…
View Post 5 min This content is machine translated Heart failure Pharmacotherapy in HFrEF and HFmrEF – Combination of four as gold standard. Important therapeutic goals in chronic heart failure are to improve quality of life and to reduce the risk of hospitalization and mortality. According to current evidence, guideline-based therapy with the…
View Post 6 min This content is machine translated Heart failure Dapagliflozin now approved in preserved ejection fraction [1,4]** After dapagliflozin had been approved for some time for heart failure with reduced ejection fraction, Swissmedic now granted an indication extension for heart failure with mildly reduced or preserved ejection…
View Post 4 min This content is machine translated SGLT-2 inhibitors Dapagliflozin now also available for non-diabetics for the treatment of heart failure (HFrEF) Based on the results of the DAPA-HF study, Swissmedic has approved dapagliflozin for the treatment of heart failure with reduced ejection fraction (HFrEF), whether or not patients have type 2…
View Post 5 min This content is machine translated Heart failure Guideline-based therapy: do’s & don’ts In addition to the groundbreaking new discovery of dapagliflozin as an effective and safe add-on therapy option in heart failure, there are several other interesting updates. Potassium levels are an…
View Post 4 min This content is machine translated AHA Scientific Sessions 2018 Dapagliflozin reduces heart failure hospitalization rate Diabetes is associated with an increased cardiovascular risk, which should be taken into account therapeutically. In 2015, the EMPA-REG OUTCOME study demonstrated positive cardiovascular effects of the SGLT-2 inhibitor empagliflozin.…
View Post 3 min This content is machine translated Type 2 diabetes SGLT-2 inhibitors: a new oral therapy option Dapagliflozin, a potent new selective SGLT-2 inhibitor, is available in many countries for use in type 2 diabetes patients either as add-on combination therapy when other glucose-lowering medical agents together…
